Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection

AIDS

Volumn 30, Issue 3, 2016, Pages 405-414

  Ofotokun, Ighovwerha ^a   Titanji, Kehmia ^a   Vunnava, Aswani ^a   Roser Page, Susanne ^b   Vikulina, Tatyana ^a   Villinger, Francois ^a,c   Rogers, Kenneth ^a,c   Sheth, Anandi N ^a   Lahiri, Cecile Delille ^a   Lennox, Jeffrey L ^a   Neale Weitzmann, M ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR ALPHA; ANTIRETROVIRUS AGENT; TNFSF11 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BONE TURNOVER; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; MALE; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; ADOLESCENT; AGED; ANIMAL; BLOOD; CD4 LYMPHOCYTE COUNT; COMPLICATION; HIV INFECTIONS; IMMUNOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; TIME FACTOR; VERY ELDERLY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTI-RETROVIRAL AGENTS; BONE RESORPTION; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANK LIGAND; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD; YOUNG ADULT;

EID: 84957872862     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000918     Document Type: Article

References (54)

1. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000; 14:F63-67.
2. Thomas J, Doherty SM. HIV infection-a risk factor for osteoporosis. J Acquir Immune Defic Syndr 2003; 33:281-291.
3. Ofotokun I, Weitzmann MN. HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture. Curr Opin Endocrinol Diabetes Obes 2010; 17:523-529.
4. Stone B, Dockrell D, Bowman C, McCloskey E. HIV and bone disease. Arch Biochem Biophys 2010; 503:66-77.
5. Arora S, Agrawal M, Sun L, Duffoo F, Zaidi M, Iqbal J. HIV and bone loss. Curr Osteoporos Rep 2010; 8:219-226.
6. Ofotokun I, Weitzmann MN. HIV and bone metabolism. Discov Med 2011; 11:385-393.
7. Cotter AG, Mallon PW. The effects of untreated and treated HIV infection on bone disease. Curr Opin HIV AIDS 2014; 9:17-26.
8. Yin MT, Lund E, Shah J, Zhang CA, Foca M, Neu N, et al. Lower peak bone mass and abnormal trabecular and cortical microarchitecture in young men infected with HIV early in life. AIDS 2014; 28:345-353.
9. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20:2165-2174.
10. Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, del Rio L, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 2010; 24:2827-2833.
11. Sharma A, Flom PL, Weedon J, Klein RS. Prospective study of bone mineral density changes in aging men with or at risk for HIV infection. AIDS 2010; 24:2337-2345.
12. Yin MT, McMahon DJ, Ferris DC, Zhang CA, Shu A, Staron R, et al. Low bone mass and high bone turnover in postmenopau-sal human immunodeficiency virus-infected women. J Clin Endocrinol Metab 2010; 95:620-629.
13. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93:3499-3504.
14. Prior J, Burdge D, Maan E, Milner R, Hankins C, Klein M, et al. Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int 2007; 18:1345-1353.
15. Young B, Dao CN, Buchacz K, Baker R, Brooks JT. Increased rates of bone fracture among HIV-infected persons in the HIV outpatient study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis 2011; 52:1061-1068.
16. Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, Gulanski B, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 2011; 6:e17217.
17. Prieto-Alhambra D, Guerri-Fernandez R, De Vries F, Lalmohamed A, Bazelier M, Starup-Linde J, et al. HIV infection and its association with an excess risk of clinical fractures: a nationwide case-control study. J Acquir Immune Defic Syndr 2014; 66:90-95.
18. Brainsky A, Glick H, Lydick E, Epstein R, Fox KM, Hawkes W, et al. The economic cost of hip fractures in community-dwelling older adults: a prospective study. J Am Geriatr Soc 1997; 45:281-287.
19. Kates SL, Kates OS, Mendelson DA. Advances in the medical management of osteoporosis. Injury 2007; 38 (Suppl 3):S17-23.
20. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteo-poros Int 2006; 17:1726-1733.
21. Lewis JR, Hassan SK, Wenn RT, Moran CG. Mortality and serum urea and electrolytes on admission for hip fracture patients. Injury 2006; 37:698-704.
22. Bass E, French DD, Bradham DD, Rubenstein LZ. Risk-adjusted mortality rates of elderly veterans with hip fractures. Ann Epidemiol 2007; 17:514-519.
23. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007; 22:465-475.
24. McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 2010; 51:937-946.
25. Brown TT, Hoy J, Borderi M, Guaraldi G, Renjifo B, Vescini F, et al. Recommendations for evaluation and management of bone disease in HIV. Clin Infect Dis 2015; 60:1242-1251.
26. Hui SL, Slemenda CW, Johnston CC Jr. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988; 81:1804-1809.
27. Weitzmann MN. T-cells and B-cells in osteoporosis. Curr Opin Endocrinol Diabetes Obes 2014; 21:461-467.
28. Vikulina T, Fan X, Yamaguchi M, Roser-Page S, Zayzafoon M, Guidot DM, et al. Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci USA 2010; 107:13848-13853.
29. Titanji K, Vunnava A, Sheth AN, Delille C, Lennox JL, Sanford SE, et al. Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection. PLoS Pathog 2014; 10:e1004497.
30. Yin MT, Lu D, Cremers S, Tien PC, Cohen MH, Shi Q, et al. Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr 2010; 53:202-208.
31. Bolland MJ, Grey A. HIV and low bone density: responsible party, or guilty by association? IBMS Bone KEy 2011; 8:7-15.
32. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009; 51:554-561.
33. Piso RJ, Rothen M, Rothen JP, Stahl M. Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used. J Acquir Immune Defic Syndr 2011; 56:320-324.
34. Tebas P, Umbleja T, Dube MP, Parker R, Mulligan K, Roubenoff R, et al. Initiation of ART is associated with bone loss independent of the three specific ART regimens: results of ACTG A5005s. 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles, California, USA.
35. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity 2013; 39:633-645.
36. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402:304-309.
37. Taubman MA, Kawai T. Involvement of T-lymphocytes in periodontal disease and in direct and indirect induction of bone resorption. Crit Rev Oral Biol Med 2001; 12:125-135.
38. Teng YT. The role of acquired immunity and periodontal disease progression. Crit Rev Oral Biol Med 2003; 14:237-252.
39. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003; 111:1221-1230.
40. Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 2006; 116:1186-1194.
41. Ofotokun I, McIntosh E, Weitzmann MN. HIV: inflammation and bone. Curr HIV/AIDS Rep 2012; 9:16-25.
42. Ofotokun I, Titanji K, Vikulina T, Roser-Page S, Yamaguchi M, Zayzafoon M, et al. Role of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss. Nat Commun 2015; 6:8282.
43. C-terminal telopetide of Collagen Crosslaps ELISA by Immuno-diagnostic Systems Inc. FHAhwgcustrjqesswc.
44. Osteocalcin N-mid ELISA by Immunodiagnostic Systems Inc. FHAhwa-ockN-MOEAoS, 2015.
45. Total soluble RANKL ELISA by Immundiagnostik AG (Bensheim GpfAIS, NH). http://www.immundiagnostik.com/en/home/pro ducts/kits-assays/skeletal-system.html?tx-mokom01immunpro dukte-pi1%5Ban%5D=K 1016&tx-mokom01immunproduk te-pi1%5Bag%5D=401&cHash=3f41023601. [Accessed 27 September 2015]
46. TNFa ELISA R&D Systems. https://www.rndsystems.com/pro ducts/human-tnf-alpha-quantikine-elisa-kit-dta00c. [Accessed 27 September 2015]
47. Hornung RW, Reed LD. Estimation of average concentration in the presence of nondetectable values. Appl Occup Environ Hyg 1990; 5:46-51.
48. Grant PM, Kitch D, McComsey GA, Dube MP, Haubrich R, Huang J, et al. Low baseline CD4R count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis 2013; 57:1483-1488.
49. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999; 25:255-259.
50. Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Woodring J, et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 2000; 106:1229-1237.
51. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106:1481-1488.
52. Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ. TNFalpha potently activates osteoclasts, through a direct action inde-pendentof and strongly synergistic with RANKL. Endocrinology 2002; 143:1108-1118.
53. Franco JM, Rubio A, Martinez-Moya M, Leal M, Merchante E, Sanchez-Quijano A, et al. T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy. Blood 2002; 99:3702-3706.
54. Kalayjian RC, Spritzler J, Pu M, Landay A, Pollard RB, Stocker V, et al. Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease. J Infect Dis 2005; 192:1577-1587.